Cash conversion trending down
Cash conversion (CFO ÷ profit) has averaged 1.21× over the last 3 profit-making years versus 1.98× before that.
Importance 64 / 95 · cash quality
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Cash conversion (CFO ÷ profit) has averaged 1.21× over the last 3 profit-making years versus 1.98× before that.
Importance 64 / 95 · cash quality
Total debt is down from ₹9,893 to ₹4,082 over 7 years (58.7% lower); debt-to-equity moved 0.22× → 0.05×.
Importance 63 / 95 · financial health
Revenue grew 11.2% but profit grew 5.0%, so the company kept less of each rupee of revenue as profit.
Importance 62 / 95 · growth
Profit has swung sharply over 7 years (from ₹2,272 to ₹11,509) — one year is a weak guide to the earnings power.
Importance 58 / 95 · growth
Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.
Peer set used on this page: 12 pharmaceuticals.
Revenue grew 10.5% a year over 7 years, from ₹29,066 cr in FY2019 to ₹58,462 cr in FY2026. Net profit grew 20.0% a year over the same period.
Revenue grew 11.2% but profit grew 5.0%, so the company kept less of each rupee of revenue as profit.
Rule PROFIT_SLOWER_THAN_REVENUE
Profit has swung sharply over 7 years (from ₹2,272 to ₹11,509) — one year is a weak guide to the earnings power.
Over 7 years profit compounded at 20.0% a year while revenue compounded at 10.5% a year — though FY2023 saw a one-off step-change of 151% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.
Revenue has compounded at 10.5% a year over 7 years (₹29,066 → ₹58,462) — steady rather than rapid.
In Q2 FY27 (Jul–Sep 2026), revenue was ₹16,199 cr (up 11.9% on the same quarter last year) and net profit ₹1,995 cr (down 36.2%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 net profit was ₹1,995 cr, down 36.2% from ₹3,125 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Q2 FY27 net profit declined 36.2% vs the same quarter last year, reversing the growth seen in the two preceding quarters (+25.8% and +26.5%).
Rule QTR_TREND_REVERSAL
Q2 FY27 net profit declined 36.2% while revenue grew 11.9% vs the same quarter last year — a gap of 48.0 percentage points.
Rule QTR_PROFIT_VS_REVENUE_GROWTH
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 13,675 | +10.5% | 2,913 | +13.8% | 21.3% |
| Q4 FY25 | 12,959 | +8.1% | 2,154 | −19.0% | 16.6% |
| Q1 FY26 | 13,851 | +9.5% | 2,293 | −19.8% | 16.6% |
| Q2 FY26 | 14,478 | +8.9% | 3,125 | +2.9% | 21.6% |
| Q3 FY26 | 15,521 | +13.5% | 3,381 | +16.1% | 21.8% |
| Q4 FY26 | 14,612 | +12.8% | 2,710 | +25.8% | 18.5% |
| Q1 FY27 | 15,300 | +10.5% | 2,901 | +26.5% | 19.0% |
| Q2 FY27 | 16,199 | +11.9% | 1,995 | −36.2% | 12.3% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 33.7% in FY2026, against 25.2% in FY2019. ROE was 14.7% and ROCE 20.7% in FY2026.
Margin and return trends are shown above.
It had little or no debt in FY2026 (debt-to-equity 0.05x). Operating cash flow was 1.08x net profit.
Cash conversion (CFO ÷ profit) has averaged 1.21× over the last 3 profit-making years versus 1.98× before that.
Rule CASH_CONVERSION_DETERIORATING
Total debt is down from ₹9,893 to ₹4,082 over 7 years (58.7% lower); debt-to-equity moved 0.22× → 0.05×.
Operating cash flow has matched or exceeded reported profit in 5 of the last 6 profit-making years (latest 1.08×).
Free cash flow has been positive in 6 of the last 6 years.
Within its 12-company Pharmaceuticals peer group, it ranks 6 of 12 on return on equity and 2 of 12 on EBITDA margin. Its P/E of 41.2 compares with a peer median of 45.3.
Ranked against 12 pharmaceuticals (FY2026, consolidated). No peer-relative rule fired for this company.
SUNPHARMA · 8th of 12 · set median 14.8%
SUNPHARMA · 2nd of 12 · set median 28.7%
SUNPHARMA · 6th of 12 · set median 14.4%
SUNPHARMA · 5th of 12 · set median 45.3×
On the trailing twelve months. Last full year: P/E 39.3× · P/S 7.5× · ROE 14.7%.
The share price is up 6.1% over 1 year, up 56.9% over 3 years (16.2% a year) and up 138% over 5 years (19.0% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 5.8% below its 52-week high.
Over 5 years profit compounded at 38.3% a year while the stock returned 19.0% a year — but FY2021 profit (₹2,272) was well below the through-cycle level (~₹6,342), so this rate is inflated by the recovery from a low base.
Rule STOCK_LAGGED_EARNINGS · recovery
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 29,066 | 32,838 | 33,498 | 38,654 | 43,886 | 48,497 | 52,578 | 58,462 |
| Total income | 30,091 | 33,473 | 34,334 | 39,576 | 44,520 | 49,851 | 54,543 | 60,434 |
| EBITDA | 7,333 | 7,626 | 9,327 | 11,319 | 12,281 | 14,377 | 17,237 | 19,703 |
| Profit before tax | 3,810 | 5,010 | 2,799 | 4,481 | 9,408 | 11,088 | 13,752 | 15,119 |
| Net profit | 3,208 | 4,172 | 2,272 | 3,389 | 8,513 | 9,610 | 10,965 | 11,509 |
| EPS (₹) | 11.1 | 15.7 | 12.1 | 13.6 | 35.3 | 39.9 | 45.6 | 47.8 |
| Net worth | 44,723 | 49,125 | 49,480 | 51,066 | 59,315 | 67,106 | 72,486 | 83,880 |
| Total debt | 9,893 | 7,578 | 3,343 | 931 | 6,198 | 2,846 | 1,870 | 4,082 |
| Operating cash flow | — | — | 6,170 | 8,985 | 4,959 | 12,135 | 14,072 | 12,419 |
| Free cash flow | — | — | 5,000 | 7,550 | 2,895 | 9,964 | 12,005 | 8,906 |
| Ratio | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Growth | ||||||||
| Revenue growth YoY | — | 13.0 | 2.0 | 15.4 | 13.5 | 10.5 | 8.4 | 11.2 |
| Profit growth YoY | — | 30.1 | -45.5 | 49.2 | 151.2 | 12.9 | 14.1 | 5.0 |
| Profitability | ||||||||
| EBITDA margin % | 25.2 | 23.2 | 27.8 | 29.3 | 28.0 | 29.6 | 32.8 | 33.7 |
| Net margin % | 10.7 | 12.5 | 6.6 | 8.6 | 19.1 | 19.3 | 20.1 | 19.0 |
| Return on equity % | 7.2 | 8.9 | 4.6 | 6.7 | 15.4 | 15.2 | 15.7 | 14.7 |
| Return on capital % | 10.2 | 10.0 | 13.2 | 17.5 | 16.6 | 17.5 | 20.3 | 20.7 |
| Leverage & cash | ||||||||
| Debt to equity | 0.22 | 0.15 | 0.07 | 0.02 | 0.10 | 0.04 | 0.03 | 0.05 |
| Cash flow ÷ profit | — | — | 2.72 | 2.65 | 0.58 | 1.26 | 1.28 | 1.08 |
| Current ratio | 1.79 | 2.02 | 1.89 | 2.04 | 2.00 | 2.56 | 2.89 | 2.82 |